{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-061599","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.279743+00:00","generated_at":"2026-06-25T12:23:11.787219+00:00","sec_items":["1.01","5.03","2.01","3.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea completes acquisition of Atrin; appoints Oren Gilad as CEO, new directors","bullets":["Issued 1,117,394 common shares and 2,949,630 Series A Preferred (each convertible into 10 common) to Atrin securityholders.","Certain stockholders agreed to 180-day lock-up on sale of shares received in merger.","CVRs entitle Aprea legacy holders to cash from disposition of mutant p53 assets within 2 years.","Oren Gilad appointed President, to become CEO; Christian Schade to stay as Executive Chairman for 6 months.","Aprea notified Nasdaq of audit committee vacancy due to director resignation; intends to regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-061599","json":"https://secwatch.observer/filing/0001104659-22-061599.json","markdown":"https://secwatch.observer/filing/0001104659-22-061599.md","text":"https://secwatch.observer/filing/0001104659-22-061599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:23:11.787219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"061fb40c53","claim":"Fouad Namouni resigned as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4d6c20d3fb","claim":"Rif Pamukcu was appointed as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Michael Grissinger and Rif Pamukcu were appointed as Class II directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"84637ba803","claim":"Michael Grissinger was appointed as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Michael Grissinger and Rif Pamukcu were appointed as Class II directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b32dcf22ee","claim":"Michael A. Kelly resigned as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b341b00417","claim":"Greg Korbel was appointed as Chief Operating Officer at Aprea Therapeutics, Inc..","evidence_excerpt":"the appointment of Greg Korbel to the position of the Chief Operating Officer of Aprea","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"ce5f18dea9","claim":"Oren Gilad was appointed as Chief Executive Officer at Aprea Therapeutics, Inc..","evidence_excerpt":"Effective as of the conclusion of the Stockholders’ Meeting, Dr. Gilad will be appointed to the position of Chief Executive Officer of Aprea, to fill the vacancy created by Christian S. Schade’s resignation as Chief Executive Officer of Aprea","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e3ea119325","claim":"Christian S. Schade resigned as Chief Executive Officer at Aprea Therapeutics, Inc..","evidence_excerpt":"Effective as of the conclusion of the Stockholders’ Meeting, Christian S. Schade will resign as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e4981c035e","claim":"Oren Gilad was appointed as President at Aprea Therapeutics, Inc..","evidence_excerpt":"the appointment of Oren Gilad, Ph.D. to the position of the President of Aprea","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"efbf82b1f7","claim":"Marc Duey was appointed as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Marc Duey was appointed as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f7e6659c6a","claim":"Oren Gilad was appointed as Director at Aprea Therapeutics, Inc..","evidence_excerpt":"Dr. Gilad was appointed as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}